Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Oncology Right
  3. Retevmo (selpercatinib) tablets Right
  4. How are Retevmo® (selpercatinib) tablets supplied?
Search Retevmo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Retevmo ® (selpercatinib) tablets

40 mg, 80 mg, 120 mg, 160 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How are Retevmo® (selpercatinib) tablets supplied?

In the second half of 2024, Retevmo® (selpercatinib) will be supplied as film-coated tablets in strengths of 40 mg, 80 mg, 120 mg, and 160 mg.

US_cFAQ_SEL307_HOW_SUPPLIED
US_cFAQ_SEL307_HOW_SUPPLIEDen-US

Selpercatinib Tablet Supply

Selpercatinib tablets will be available in 40 mg, 80 mg, 120 mg, and 160 mg dosage strengths.1

Selpercatinib Tablet Supply provides a description of how selpercatinib tablets are supplied. 

Selpercatinib Tablet Description1

Tablet Strength

Description

Package Configuration

NDC Number

40 mg

Light gray, film coated, round tablets debossed with “Ret 40” on one side and “5340” on the other side

60 count bottle

NDC 0002-5340-60

80 mg

Dark red-purple, film coated, round tablets
debossed with “Ret 80” on one side and ”6082” on the other side

60 count bottle

NDC 0002-6082-60

120 mg

Light purple, film coated, round tablets debossed with “Ret 120” on one side and “6120” on the other side

60 count bottle

NDC 0002-6120-60

160 mg

Light pink, film coated, round tablets debossed with Ret “160” on one side and “5562” on the other side

60 count bottle

NDC 0002-5562-60

Abbreviation: NDC = national drug code

Enclosed Prescribing Information

RETEVMO® (selpercatinib) capsules and tablets, for oral use, Lilly

Reference

1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

Date of Last Review: April 05, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly